With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Atrial fibrillation is associated with a high risk for stroke, myocardial infarction, heart failure, and death. How does blockade of the renin-angiotensin system affect patient outcomes? Join our international panel of experts, Drs Camm, Connolly, Crijns, and Granger, as they discuss the ESC 09 hotline results of the ACTIVE-I trial.
Dr. Jeroen Bax, on the cusp of publishing a landmark paper to validate the role of MIBG imaging in risk stratifying patients with heart failure, provides a snapshot of his study in this interview from Europace 2009.
How can we reduce the time taken to accurately diagnose ACS? ECGs and biomarkers may be nondiagnostic, even the presenting symptoms can vary or be absent. As every 30 minutes delay is associated with a 7.5% relative increase in mortality, time is indeed muscle. Join Drs. Gibson, Pride, Santini, and Krucoff as they present new insights into this complex field.
Atrial fibrillation (AF) is the most frequently occurring cardiac arrhythmia affecting some 2.2 million Americans with often serious clinical consequences.. Join Drs. Bhatt, Connolly and Camm for a discussion on the risk factors, management challenges, and new data on treatment options for patients with AF
Sudden cardiac death (SCD) affects all age groups and can occur in any setting. While rare, sudden death among young adults is a devastating occurrence, diagnostic evaluation using echocardiography and ECGs as screening instruments in addition to a thorough history and physical examination may help identify young individuals at risk for SCD. Click to take the survey and compare answers. The results will help us create future CME programming.
The world's first MR-conditional pacemaker system designed for safe use in MRI represents a major milestone in the evolution of ICDs. Dr. Bruce Wilkoff from the Cleveland Clinic speaks on the significance of having this new technology available to patients.
Join Drs. Prystowsky, Lau, and Oseroff as they provide an international perspective on the prevention of sudden cardiac arrest in the Pacific Rim and South America.
Identifying appropriate patients for cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs) is crucial for the prevention of sudden cardiac arrest as well as for cardiac resynchronization.
Can genetic screening identify patients at increased risk for these cardiac events if left untreated? Join Dr Priori for a review of the current data on this rapidly evolving topic.
What is the prevalence and clinical impact of lead failure on the patient and their QOL? Our panel of experts, Drs Ellenbogen, Epstein, Wilkoff, and Auricchio discuss evidence-based strategies for managing this important issue.
Warfarin remains the cornerstone of stroke prevention in patients with AF. However, many patients are unable or unwilling to take it. Could antiplatelet therapy fill this gap? How might investigational anticoagulants change the playing field? Dr Naccarelli leads a panel discussion with Drs Connolly and Camm.
Data have shown that less than 40% of eligible patients hospitalized for heart failure received ICDs. Rates of use among women and black patients were significantly lower than among white men. Join Drs Fonarow, Hernandez, and Peterson in a lively discussion in how to overcome these disparities.
